Company Overview
Snapshot
Founded in January 2023 by Raviv Pryluk, Dan Goldstaub, and Elad Berkman, PhaseV has 11–50 employees and has raised $65 million across two funding rounds. The company secured a $50 million Series A round in May 2025, led by Accel and Insight Partners.
Business overview
PhaseV develops a platform for adaptive clinical trial design and closed-loop execution, leveraging an intuitive user interface and flexible software architecture. The company utilizes cutting-edge algorithms, including reinforcement learning and causal machine learning, to support key clinical decisions throughout the trial process. PhaseV operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Clinical Workflow, serving the healthcare industry and laboratories.
Strategic signal
In March 2026, PhaseV launched its AI Conductor, a centralized platform designed to automate clinical workflows from protocol to submission. This development signals a strategic move towards enhancing efficiency and reducing manual overhead in clinical trials, indicating the company's commitment to leveraging AI for end-to-end process optimization and accelerating drug development timelines for investors and innovation teams.
Log in to access full profile ›Company Intelligence Q&A
- What was PhaseV's most recent funding round?
- In May 2025, PhaseV completed a $50 million Series A funding round. The round was co-led by Accel and Insight Partners.
- When was PhaseV founded and by whom?
- PhaseV was founded in January 2023 by co-founders Raviv Pryluk, Dan Goldstaub, and Elad Berkman.
- What is the purpose of PhaseV's AI Conductor?
- In March 2026, PhaseV launched its AI Conductor, a centralized platform that automates clinical workflows from protocol to submission, aiming to streamline and accelerate the clinical development process.
- Has PhaseV announced any significant partnerships recently?
- In May 2025, PhaseV announced a strategic partnership with the Crohn's & Colitis Foundation to advance Inflammatory Bowel Disease (IBD) research.
- What new platform capabilities did PhaseV unveil in 2024?
- In September 2024, PhaseV unveiled the latest capabilities of its AdaptV platform, which is powered by machine learning to improve oncology clinical trials.